- Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
- Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
- Ocugen to Present at Investing in Cures Summit
- Ocugen Clinical Showcase Webcast Now Available
- Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
- Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
- Ocugen to Present at 2024 BIO CEO & Investor Conference
- Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
- Ocugen to Present at Pharma Market Research Conference
- Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
More ▼
Key statistics
On Thursday, Ocugen Inc (OCGN:NAQ) closed at 1.64, -22.09% below its 52-week high of 2.11, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.75 |
---|---|
High | 1.76 |
Low | 1.57 |
Bid | 1.64 |
Offer | 1.65 |
Previous close | 1.78 |
Average volume | 17.97m |
---|---|
Shares outstanding | 256.50m |
Free float | 252.78m |
P/E (TTM) | -- |
Market cap | 420.66m USD |
EPS (TTM) | -0.3242 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼